Fumero GFY, Cárdenas CD, Piloto DI, Fernández AL, Sánchez POA, Socarrás SLM

Language: Spanish
References: 0
Page: 1-6
PDF size: 83.97 Kb.

ABSTRACT

Glaucoma surgery is a therapeutic alternative aimed at reducing the intraocular pressure when there is no response to non-surgical medical treatment. In the last few years, glaucoma surgery has remarkably evolved. New devices, capable of achieving pressure management with minor complications, have emerged. The term MIGS (minimally invasive glaucoma surgery) is reserved only for those techniques that favor aqueous humor drainage ab-interno approach through clear corneal incision and usually a biocompatible device is placed into the anterior chamber angle. The ExPRESS, Trabectome, iStent and recently Cypass (July 2016) are the only devices approved by the Food and Drug Enforcement Agency (FDA). Hydrus and Xen are still pending on approval. Nevertheless, it is required that most of them prove their success in the course of time.